128 related articles for article (PubMed ID: 36317868)
1. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
[TBL] [Abstract][Full Text] [Related]
2. TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.
Hudock TR; Barker VR; Manley BJ; Chobrutskiy A; Chobrutskiy BI; Diaz MJ; Song JJ; Blanck G
Cancer Biomark; 2023; 38(1):103-110. PubMed ID: 37545223
[TBL] [Abstract][Full Text] [Related]
3. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.
Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
[TBL] [Abstract][Full Text] [Related]
4. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.
Chobrutskiy BI; Yeagley M; Diviney A; Zaman S; Gozlan EC; Tipping P; Koohestani DM; Roca AM; Blanck G
Immunology; 2020 Apr; 159(4):373-383. PubMed ID: 31821535
[TBL] [Abstract][Full Text] [Related]
5. Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.
Patel AR; Patel DN; Tu YN; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Biomol Struct Dyn; 2023 Jul; 41(10):4632-4640. PubMed ID: 35538689
[TBL] [Abstract][Full Text] [Related]
6. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity.
Eakins RA; Chobrutskiy A; Teer JK; Patel DN; Hsiang M; Huda TI; Zaman S; Sexton WJ; Coppola D; Falasiri S; Blanck G; Chobrutskiy BI
Mol Immunol; 2022 Oct; 150():58-66. PubMed ID: 35987136
[TBL] [Abstract][Full Text] [Related]
7. Chemical Complementarity of Tumor Resident, Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
Viral Immunol; 2023 Dec; 36(10):669-677. PubMed ID: 38052065
[TBL] [Abstract][Full Text] [Related]
8. Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer.
Waweru JW; Mwangi KW; Barker VR; Gozlan EC; Yeagley M; Blanck G; Makokha FW
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4359-4366. PubMed ID: 36098856
[TBL] [Abstract][Full Text] [Related]
9. Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
Agnila DRL; Huda TI; Eakins RA; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Melanoma Res; 2023 Aug; 33(4):275-282. PubMed ID: 37222076
[TBL] [Abstract][Full Text] [Related]
10. Electrostatic Complementarities of Glioblastoma-Resident T-Cell Receptors and Cancer Testis Antigens Linked to Poor Outcomes and High Levels of Sphingosine Kinase-2 Expression.
Arias MA; Cios KJ; Kacsoh DB; Montgomery BE; Song JJ; Patel AR; Chobrutskiy A; Chobrutskiy BI; Blanck G
Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106775
[TBL] [Abstract][Full Text] [Related]
11. Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression.
Pakasticali N; Chobrutskiy A; Patel DN; Hsiang M; Zaman S; Cios KJ; Blanck G; Chobrutskiy BI
Cancer Inform; 2023; 22():11769351231177269. PubMed ID: 37313373
[TBL] [Abstract][Full Text] [Related]
12. An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.
Cheng P; Cios KJ; Varkhedi M; Barker VR; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Oncoscience; 2023; 10():59-66. PubMed ID: 37953875
[TBL] [Abstract][Full Text] [Related]
13. TRB CDR3 chemical complementarity with HBV epitopes correlates with increased hepatocellular carcinoma, disease-free survival.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
J Med Virol; 2023 Aug; 95(8):e29043. PubMed ID: 37621059
[TBL] [Abstract][Full Text] [Related]
14. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
[TBL] [Abstract][Full Text] [Related]
15. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer.
Chobrutskiy BI; Zaman S; Diviney A; Mihyu MM; Blanck G
J Cancer Res Clin Oncol; 2019 Mar; 145(3):615-623. PubMed ID: 30539280
[TBL] [Abstract][Full Text] [Related]
16. Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas.
Yeagley M; Chobrutskiy BI; Gozlan EC; Medikonda N; Patel DN; Falasiri S; Callahan BM; Huda T; Blanck G
Pediatr Hematol Oncol; 2021 Apr; 38(3):251-264. PubMed ID: 33616477
[TBL] [Abstract][Full Text] [Related]
17. Tumor resident, TRA anti-viral CDR3 chemical sequence motifs are associated with a better breast cancer outcome.
Diaz MJ; Kacsoh DB; Patel DN; Yeagley M; Hsiang M; Blanck G
Genes Immun; 2023 Apr; 24(2):92-98. PubMed ID: 36805542
[TBL] [Abstract][Full Text] [Related]
18. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma.
Kacsoh DB; Diaz MJ; Gozlan EC; Sahoo A; Song JJ; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12047-12056. PubMed ID: 37421457
[TBL] [Abstract][Full Text] [Related]
19. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
20. A Bioinformatics Assessment Indicating Better Outcomes With Breast Cancer Resident, Immunoglobulin CDR3-MMP2 Binding.
Mandala SR; Thomson AJ; Gozlan EC; Patel DN; Chobrutskiy A; Chobrutskiy BI; Blanck G
Cancer Genomics Proteomics; 2023; 20(3):239-246. PubMed ID: 37093687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]